T
Tsai Sheng Yang
Researcher at Memorial Hospital of South Bend
Publications - 9
Citations - 5237
Tsai Sheng Yang is an academic researcher from Memorial Hospital of South Bend. The author has contributed to research in topics: Hepatocellular carcinoma & Internal medicine. The author has an hindex of 4, co-authored 5 publications receiving 4549 citations. Previous affiliations of Tsai Sheng Yang include Chang Gung University.
Papers
More filters
Journal ArticleDOI
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Ann-Lii Cheng,Yoon-Koo Kang,Zhendong Chen,Chao Jung Tsao,Shukui Qin,Jun Suk Kim,Rongcheng Luo,Jifeng Feng,Sheng-Long Ye,Tsai Sheng Yang,Jianming Xu,Yan Sun,Houjie Liang,Jiwei Liu,Jiejun Wang,Won Young Tak,Hongming Pan,Karin Burock,Jessie Zou,D. Voliotis,Zhongzhen Guan +20 more
TL;DR: Sorafenib is effective for the treatment of advanced hepatocellular carcinoma in patients from the Asia-Pacific region, and is well tolerated.
Journal ArticleDOI
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III Sorafenib Asia–Pacific trial
Ann-Lii Cheng,Zhongzhen Guan,Zhendong Chen,Chao Jung Tsao,Shukui Qin,Jun Suk Kim,Tsai Sheng Yang,Won Young Tak,Hongming Pan,Shiying Yu,Jianming Xu,Fang Fang,Jessie Zou,Giuseppe Lentini,D. Voliotis,Yoon-Koo Kang +15 more
TL;DR: Experimental analyses suggest that sorafenib is effective for patients from the AP region with advanced HCC, irrespective of baseline status, and the efficacy and safety profiles in the subpopulations described were comparable with those in the overall study population.
Journal ArticleDOI
Vandetanib in patients with inoperable hepatocellular carcinoma: A phase II, randomized, double-blind, placebo-controlled study
Chiun Hsu,Tsai Sheng Yang,Teh Ia Huo,Ruey Kuen Hsieh,Chih-Wei Yu,Wei Shou Hwang,Tsai Yuan Hsieh,Wen Tsung Huang,Yee Chao,Robin Meng,Ann-Lii Cheng +10 more
TL;DR: Although trends of improved PFS and OS after vandetanib treatment were found, they were statistically insignificant and the safety profile was consistent with previous studies.
Journal ArticleDOI
Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study
Ann-Lii Cheng,Gerardo H. Cornelio,Lin Shen,Timothy J. Price,Tsai Sheng Yang,Ik Joo Chung,Guang Hai Dai,Jen Kou Lin,Atul Sharma,Kun-Huei Yeh,Brigette B.Y. Ma,Adel Zaatar,Zhongzhen Guan,Nehal Masood,Vichien Srimuninnimit,Thomas Yau,Peter Gibbs,Xiuwen Wang,Dinesh Chandra Doval,Seung Taek Oh,Byoung Yong Shim,Charity Gorospe,Hwei Ming Wang,Ekaphop Sirachainan,Andrew Hill,Kwang Wook Suh,Frank Beier,Sudipto Chatterjee,Robert Lim +28 more
TL;DR: Efficacy results appeared similar for patients treated with FOLFOX and FOLFIRI, suggesting once‐every‐2‐weeks cetuximab is effective and tolerable as first‐line therapy and may represent an alternative to weekly administration.